TyG-BMI Can Help Predict In-Hospital Mortality in HFmrEF With Hypertension

Why It Matters

Integrating TyG‑BMI adds metabolic insight to HFmrEF risk models, enabling earlier identification of high‑risk patients and more targeted therapeutic decisions.

Key Takeaways

• TyG‑BMI strongly predicts in‑hospital mortality in hypertensive HFmrEF
• Age ≥75, high TyG‑BMI, CRP ≥10 mg/L increase risk
• ACEI/ARB/ARNI and SGLT2 inhibitors reduce mortality risk
• Non‑linear TyG‑BMI >300 sharply raises death odds
• Model validated with good discrimination and calibration

Pulse Analysis

Heart failure with mildly reduced ejection fraction occupies a gray zone between HFrEF and HFpEF, yet its patients often experience outcomes comparable to more severe phenotypes. When hypertension co‑exists, the metabolic burden intensifies, exposing a gap in conventional risk scores that focus primarily on hemodynamic parameters. Clinicians therefore need tools that capture the interplay between cardiovascular stress and metabolic dysfunction, especially as the prevalence of insulin‑resistance syndromes rises globally.

The TyG‑BMI metric blends fasting triglycerides, glucose, and body‑mass index into a single index that reflects systemic insulin resistance and adiposity. Prior research linked TyG‑BMI with atherosclerotic events, but its application to HFmrEF is novel. The study’s multivariate analysis revealed a four‑fold increase in mortality odds per 100‑unit TyG‑BMI rise, underscoring a non‑linear risk surge beyond a threshold of 300. This dose‑response pattern suggests that metabolic derangements may act as a catalyst for decompensation in an already vulnerable cardiac substrate.

From a practice standpoint, adding TyG‑BMI to existing prognostic models could sharpen triage decisions, prompting earlier initiation of disease‑modifying therapies such as ACEI/ARB/ARNI combos and SGLT2 inhibitors, which the study identified as protective. However, the findings stem from a single‑center cohort; broader, prospective validation is essential before guideline endorsement. If confirmed, TyG‑BMI could become a low‑cost, readily available biomarker that bridges the gap between metabolic health and heart‑failure management, ultimately improving resource allocation and patient outcomes.